公开(公告)号：US20070248948A1

公开(公告)日：2007-10-25

申请号：US11786980

申请日：2007-04-13

申请人： Christos Hatzis ,  W. Symmans ,  Lajos Pusztai

发明人： Christos Hatzis ,  W. Symmans ,  Lajos Pusztai

IPC分类号： C12Q1/00 ,  G06F19/00

CPC分类号： G01N33/57484 ,  G01N33/574 ,  G01N33/57415

摘要： Method of Measuring Residual Cancer and Predicting Patient Survival Disclosed is a method for determining survival and relapse of a patient undergoing therapy for a tumor by determining a residual cancer burden index based on the bidimensional diameters of a primary tumor bed of said tumor in a resection specimen, the proportion of the primary tumor bed area that contains invasive carcinoma, the number of regional lymph nodes containing metastatic carcinoma, the diameter of the largest metastasis in an regional lymph node; and the fractional reduction in lymph node size with each added positive lymph node.

摘要翻译： 测量残留癌症和预测患者生存的方法公开了一种通过根据切除标本中所述肿瘤的原发肿瘤床的二维直径确定残留癌症负担指数来确定进行肿瘤治疗的患者的存活和复发的方法 ，包括侵袭性癌的原发性肿瘤床面积比例，淋巴结转移区域淋巴结数目，淋巴结转移最大的直径; 和淋巴结大小的分数减少每个添加阳性淋巴结。

公开(公告)号：US20100178651A1

公开(公告)日：2010-07-15

申请号：US12513338

申请日：2007-11-05

申请人： Christos Hatzis ,  Fraser W Symmans ,  Lajos Pusztai

发明人： Christos Hatzis ,  Fraser W Symmans ,  Lajos Pusztai

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136

摘要： The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent.

摘要翻译： 本发明提供了在肿瘤中表达的基因的鉴定，以指示对试剂或试剂类的反应性或抗性。 更具体地说，这些基因表现出与一种药剂的反应性相关的表达或与另一类药剂相关的表达是负相关的。 本发明的一个或多个这些基因可以用作标记物（或替代标记物）来鉴定可能被响应剂成功治疗的肿瘤以及鉴定应该避免被抗药剂治疗的肿瘤。

公开(公告)号：US20050266420A1

公开(公告)日：2005-12-01

申请号：US10955054

申请日：2004-09-30

申请人： Lajos Pusztai ,  W. Symmans ,  Kenneth Hess ,  Mark Ayers ,  James Stec

发明人： Lajos Pusztai ,  W. Symmans ,  Kenneth Hess ,  Mark Ayers ,  James Stec

IPC分类号： C12Q1/68 ,  G01N33/48 ,  G01N33/50 ,  G01N33/574 ,  G06F19/00

CPC分类号： G01N33/57484 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The present invention provides the identification of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose expression (either increased expression or decreased expression) correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent.

摘要翻译： 本发明提供了在肿瘤中表达的对给定治疗剂有反应并且其表达（增加的表达或降低的表达）与对该治疗剂的反应性相关的基因的鉴定。 本发明的一个或多个基因可以用作标记物（或替代标记物）来鉴定可能被该试剂成功治疗的肿瘤。